Saturday, June 2, 2007

Sending Biotech Research to China

From the Los Angeles Times June 2, 2007

A San Diego firm is setting up a lab in Asia to save on costs.
By Evelyn Iritani

SHANGHAI — Donkey meat with garlic juice and deep-fried duck bills aren't Dajun Yang's favorite fare. But while accompanying two U.S. colleagues on a recent trip to Beijing, he made sure they were exposed to cuisine they couldn't find back home.

Culinary tour guide is just one of Yang's many unofficial jobs. As the head of the China subsidiary of San Diego-based Ascenta Therapeutics Inc., Yang also is responsible for staffing the company's new lab in Shanghai, vetting animal-testing facilities and helping colleagues navigate China's regulatory jungle.

Yang's ability to bridge the two cultures is crucial to Ascenta's big gamble: creating a new breed of biotech start-up that marries U.S. and Chinese scientific talent with China's cheap labor and resources. The firm is using technology licensed from the National Institutes of Health and the University of Michigan, where Yang and Ascenta co-founder Shaomeng Wang, both natives of China, conduct their research.

Ascenta is betting that its China subsidiary, which employs 20 scientists working for a fraction of what they would be paid in the United States, will drastically reduce the price tag — and time — of bringing its promising cancer-fighting medicines to market. Investors apparently agree. In April, the company announced it had raised $50 million, bringing its total funding to $85.5 million.

If Ascenta succeeds, biotech experts predict it could chart a new path for global drug development, helping China in its bid to leapfrog India and Eastern Europe, the current favorites for drug research outsourcing.

Ascenta is "essentially leveraging the best that both countries have to offer," said Greg Scott, a San Diego investor and editor of industry newsletter ChinaBio Today, who recently opened an office in Shanghai's Zhangjiang High-Tech Park.

The outsourcing of global drug development is risky. China's drug industry, long dominated by production of herbal and traditional medicines and generic drugs, is in the early stages of transitioning to a Western-style pharmaceutical system.

Eager to boost the credibility of its fledgling drug industry, the Chinese government has launched a major overhaul of the country's State Food and Drug Administration.

This week, the Chinese government sentenced the former head of the administration to death for reportedly taking bribes from companies trying to get approval for their drugs. During his tenure, dozens of Chinese died after ingesting fake or dangerous medicine.

U.S. executives said they were proceeding with care to ensure that their employees and subcontractors were working to U.S. standards and all research results would meet government approval in the U.S. and China. California is leading the trans-Pacific migration, thanks to its proximity to Asia and its large pool of expatriate Chinese scientists.

BioDuro Inc., a San Diego company providing contract research services to drug firms, recently opened a 40,000-square-foot lab in Beijing. Immusol Inc., a San Diego biotech firm developing anti-cancer drugs, is outsourcing chemistry work to firms in Beijing and Shanghai.

Much like how the U.S. software industry was forced to remake itself after the technology bust early this decade, the biotech industry is undergoing a painful readjustment as early-stage research moves to lower-cost countries. Ascenta's chief financial officer, Craig Kussman, came from Discovery Partners International Inc., a San Diego firm that closed up shop after it lost several large research contracts to companies in Asia.

A subsidiary in China wasn't in the business plan when Ascenta jumped into the crowded cancer field in 2003 with a compound derived from gossypol, a substance contained in cottonseed oil. Three decades earlier, Chinese health officials had traced an outbreak of male sterility in several villages to gossypol. It turned out that the villagers had been using unprocessed cottonseed oil for cooking.

World health experts discarded plans to use gossypol as a contraceptive because it was too effective; 99% of the men became sterile. But Yang and Wang picked up the trail, convinced that the protein inhibitors that killed the sperm might also trigger apoptosis, or cell death, in cancer cells. Their early research was promising.

But their timing was bad. Venture capitalists had gone into deep retreat, stung by the bursting of the technology bubble. With several promising drug candidates in the pipeline and limited funds, Ascenta's executives decided they had to figure out a way to buy more research for their dollars.

They found their answer in China, where the government had set its sights on developing a world-class biotechnology sector and was offering foreign firms cheap land, tax breaks, a huge pool of low-cost scientific talent and cheap raw materials. The savings were significant: A chemist with a doctorate earning $20,000 to $30,000 in China would be paid three to four times as much in the United States.

Ascenta Chief Executive Mel Sorenson said his company couldn't "manage the potential risks" of shipping a piece of its drug pipeline to China without Yang's expertise. "He is pivotal to our operation," the noted cancer specialist said.

Protection of intellectual property remains one of Ascenta's biggest worries. Although China has signed on to global intellectual property rules, the country is still the world's leading producer of pirated goods, including fake Viagra and Tamiflu.

Yang, who commutes regularly to China from his home in Ann Arbor, Mich., believes he can overcome that hurdle. He set up Ascenta's operation in China as a wholly owned subsidiary, which gives the parent company legal control over any discoveries made in China.

Most of Ascenta's discovery work is being done in Michigan and the promising substances are sent to Shanghai for further refinement and testing. Two compounds are in preclinical trials. The company's lead candidate, AT-101, is being studied in clinical trials in the U.S. for treatment of leukemia, lymphoma, lung cancer and prostate cancer.

Xiaolan Ling, a scientist at the prestigious Shanghai Institute of Organic Chemistry, said she joined Ascenta because she wanted to learn how to move a scientific discovery from the laboratory to the marketplace.

"This company is going to be a pioneer in China," she said.

To promote a sense of camaraderie and lessen the chances of losing talented employees like Ling, Yang has distributed stock options to his China staff.

As early movers, Ascenta's executives know their work will receive extra scrutiny from the U.S. and Chinese officials who oversee drug testing and sales in their respective countries.

Employees and contractors are required to follow internationally accepted standards for laboratory safety, sanitation and record-keeping.

"Sometimes people think there is a so-called Chinese standard," Yang said. "There's no way. There's only one standard. It's like the Olympics."

One area where Ascenta expects to reap savings of as much as 80% is in animal testing, an area where costs have skyrocketed in the United States because of limited supply, increased security costs and stringent regulations.

A company might need to conduct tests on thousands of animals to determine a compound's safety and efficacy. China has no strong animal-rights movement, a large supply of cheap animals and technicians willing to work for less than $300 a month. A rhesus monkey, which costs $5,000 to $8,000 in the United States, can be bought here for $500.

San Francisco-based Bridge Pharmaceuticals Inc. and Crown Bioscience Inc. of Palo Alto have set up modern animal-testing facilities in Beijing and are seeking international accreditation.

Yang and Jay Stoudemire, Ascenta's vice president of preclinical development, said they were proceeding with caution, having seen the dark side of this industry. They visited one monkey-breeding business in western China where the animals were crowded into a dirty, concrete facility.

"It reminded me of an apocalyptic chicken farm," said Stoudemire, who won't be acquiring animals from that business.

One of Yang's most crucial duties is cultivating relations with officials from China's State Food and Drug Administration, which is responsible for all applications to conduct drug trials or sales.

Western pharmaceutical executives say the administration is struggling to bring its operation to international standards and lacks the resources and the technical expertise to handle its expanding duties, including reviewing complex, Western-style new-drug applications. After Chinese officials launched a major corruption investigation of the administration this year, work at the agency slowed to a crawl.

Yang thinks it is too soon to conduct early-stage trials with humans in China because of the lack of experienced medical personnel and problems in data collection. But with deep-pocketed competitors such as Abbott Laboratories, Roche Group and Genentech Inc. chasing similar cancer treatments, he is keeping open the possibility that his firm might seek approval for human testing in China as early as next year.

"They are getting better," he said of the Chinese. "They are moving very, very fast."

If you want other stories on this topic, search the Archives at,1,5636059.story


Anonymous said...

[url=] mexitil discount[/url]

Anonymous said...

[url=]buy mexitil[/url]

Anonymous said...

[url=]buy Viagra tablets without prescription[/url]

Anonymous said...

happen to a stop this

Anonymous said... wolfes westci subregions abstracts schulte onwards mccausland melipilla

Anonymous said...

Amiable post and this enter helped me alot in my college assignement. Gratefulness you for your information.

lots in Costa Rica said...

I love when I have the opportunity to read blogs as interesting as this. really thanks and congratulations. Costa Rica Cheap Land for Sale

eco vacation costa rica said...

Hello congratulations you did an excellent work with this blog about Sending Biotech Research to China I would like to know more about this topic and please when you have any update contac me please to read it. thanks for sharing!!

Green Parks said...

Hello.. Firstly I would like to send greetings to all readers. After this, I recognize the content so interesting about this article. For me personally I liked all the information. I would like to know of cases like this more often. In my personal experience I might mention a book called Green Parks Costa Rica in this book that I mentioned have very interesting topics, and also you have much to do with the main theme of this article.

Anonymous said...

LAS VEGAS, Nov. 15, 2012 -- /PRNewswire/ -- Caesars Entertainment Corporation (NASDAQ: CZR) today announced that Donald Colvin will join the company as Executive Vice President and Chief Financial Officer, subject to required regulatory approvals. In this role, Colvin will be responsible for Caesars' finance functions and report to Gary Loveman, Chairman, President and Chief Executive Officer. [url=http://SWEDENONLINECASINO.COM/]slots

Anonymous said...

Anonymous said...

Wow, this post is pleasant, my younger sister is analyzing such
things, so I am going to tell her.

my web-site; please click the following website
My website: User:LolitaRein - E-jobs-observatory wiki

Anonymous said...

Hi I am so glad I found your blog page, I really found you by mistake,
while I was searching on Aol for something else, Nonetheless I am
here now and would just like to say many thanks for a fantastic
post and a all round enjoyable blog (I also love the theme/design), I don't have time to read it all at the minute but I have saved it and also included your RSS feeds, so when I have time I will be back to read a lot more, Please do keep up the excellent job.

Review my webpage - similar web page

Anonymous said...

whoah this weblog is excellent i love reading your articles.
Keep up the great work! You recognize, a lot of persons are searching round for this information, you can help them greatly.

Stop by my website :: 404 Not Found

Anonymous said...

Hello everyone, it's my first visit at this web page, and piece of writing is in fact fruitful in support of me, keep up posting these articles or reviews.

Here is my web-site :: vergleich Gesetzlicher krankenkassen

Unknown said...

Thank you very, very useful information And here on my site a lot of information in the same can be utilized Your Thanks
hotel kitchen equipment

Anonymous said...

Wow, this paragraph is good, my sister is analyzing these things, thus I
am going to convey her.

Have a look at my web site pacific island vacation

Anonymous said...

oZzy moved away earlier, I miss his cock, and i am
always hungry for intercourse.

Here is my web blog; hcg injections
Also see my webpage :: hcg injections

Anonymous said...

I enjoy, lead to I found exactly what I was taking a look for.
You've ended my 4 day long hunt! God Bless you man. Have a great day. Bye

Feel free to visit my web blog; mouse click The Following post

Anonymous said...

My brother suggested I might like this blog.
He was totally right. This post truly made my day. You can not imagine just how
much time I had spent for this information! Thanks!

Check out my page; vergleich gesetzliche krankenversicherungen

Anonymous said...

Hi, I do believe this is an excellent web site. I stumbledupon it ;) I am going to
come back once again since i have saved as a favorite it.

Money and freedom is the best way to change, may you be rich and continue to guide other people.

Also visit my web-site Next page

Anonymous said...

I like [url=]Nike[/url] and

Anonymous said...

Magnificent beat ! I would like to apprentice whilst you
amend your web site, how could i subscribe for a weblog web site?
The account helped me a acceptable deal. I had been a little bit acquainted of this your broadcast provided bright transparent idea

my homepage Related Site

Anonymous said...

Very energetic blog, I enjoyed that a lot. Will there be a part 2?

Here is my webpage ... 索引

Wanda said...

Cross cultural expertise is important.